多西紫杉醇联合表阿霉素序贯化疗对早期乳腺癌患者Ki-67表达及心肌功能的影响  

Effect on Ki-67 Expression and Myocardial Function in Patients with Early Breast Cancer by Using Docetaxel combined with Epirubicin Sequential Chemotherapy

作　　者：任潇毅[1] 吉文仲[1] REN Xiaoyi;JI Wenzhong(Second Affiliated Hospital of Zhengzhou University,Zhengzhou,450003)

机构地区：[1]郑州大学第二附属医院,450003

出　　处：《实用癌症杂志》2020年第9期1415-1418,1422,共5页The Practical Journal of Cancer

摘　　要：目的探究多西紫杉醇联合表阿霉素序贯化疗对早期乳腺癌患者Ki-67表达及心肌功能的影响。方法将乳腺癌早期患者94例随机分为对照组和观察组,每组47例。对照组采用多西紫杉醇联合表阿霉素同时使用治疗,观察组先给予表阿霉素治疗4个周期,再给予多西紫杉醇治疗4个周期。观察并比较2组患者疗效、Ki-67及其他血清指标、心肌功能、免疫功能。结果观察组总有效率为85.11%,明显高于对照组的78.72%(P<0.05)。治疗后,2组患者的Ki-67、缺氧诱导因子-1α(HIF-1α)、血管内皮生长因子(VEGF)均降低,且观察组显著低于对照组,差异具有统计学意义(P<0.05)。2组患者的肌酸激酶同工酶(CK-MB)、血清肌钙蛋白Ⅰ(cTnⅠ)均升高,左心室射血分数(LVEF)降低,其中观察组CK-MB、cTnⅠ水平显著高于对照组,差异具有统计学意义(P<0.05)。观察组患者CD4+、CD3+水平升高,且高于对照组(P<0.05);CD8+水平降低且低于对照组(P<0.05)。结论多西紫杉醇联合表阿霉素序贯化疗对早期乳腺癌患者肿瘤细胞生长抑制作用更强,对患者心肌毒性更小,值得临床推广。Objective To explore the effect on Ki-67 expression and myocardial function in patients with early breast cancer by usingdocetaxel combined with epirubicin sequential chemotherapy.Methods 94 patients with early breast cancer were randomly divided into the control group and the observation group,with 47 cases in each group.Patients in the control group were treated with docetaxel combined with epirubicin;patients in the observation group were treated with epirubicin for 4 period,docetaxel for 4 period.The curative effect,Ki-67 and other serum indexes,myocardial function and immune function were compared between the 2 groups.Results The total effective rate of the observation group was 85.11%,significantly higher than that of the control group(78.72%,P<0.05).After treatment,the levels of Ki-67,hypoxia inducible factor-1α(HIF-1α),vascular endothelial growth factor(VEGF)in the 2 groups all decreased,and those in the observation group were significantly lower than those of the control group(P<0.05).The levels of creatine kinase isoenzyme(CK-MB),serum troponinⅠ(cTnⅠ)in the 2 groups all increased,and the level of left ventricular ejection fraction(LVEF)in the 2 groups all decreased,the levels of CK-MB and cTnI in the observation group were significantly lower than those of the control group(P<0.05).The levels of CD4+,CD3+in the observation group were higher than those of the control group(P>0.05).The level of CD8+in the observation group was significantly lower than that of the control group.Conclusion Docetaxel combined with epirubicin sequential chemotherapy has stronger inhibitory effect on the growth of tumor cells in patients with early breast cancer and less toxicity to myocardium of patients,which is worthy of clinical promotion.

关 键 词：多西紫杉醇 表阿霉素 序贯化疗 早期乳腺癌 心肌损伤 KI-67 

分 类 号：R737.9[医药卫生—肿瘤]